How effective are the second generation antipsychotics?

Peter Buckley

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The past five years have witnessed a period of intense drug development for the treatment of schizophrenia. Second generation antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and sertindole are now replacing the conventional antipsychotics in the treatment of schizophrenia at each point along its illness course. While there are few studies comparing these drugs, available evidence and clinical experience suggest that their different neuroreceptor affinity profiles translate into different benefits within specific clinical situations. Their relative efficacy in treatment- refractory schizophrenia and in the management of negative symptoms is of particular importance. While clozapine is currently the treatment of choice in treatment-refractory schizophrenia, there are some data to suggest that risperidone, olanzapine and sertindole are also effective in these patients, although higher doses may be required for the treatment of patients with severe schizophrenia. The benefit of second generation antipsychotics over conventional agents in the treatment of negative symptoms is more established. However, their relative efficacy on primary and secondary negative symptoms appears to differ. Thus, although the advantages of the second generation antipsychotics over conventional agents are acknowledged, there is a clear need for head-to-head comparisons to determine their relative efficacy in treatment-refractory schizophrenia and in the control of negative symptoms.

Original languageEnglish (US)
JournalInternational Journal of Psychiatry in Clinical Practice
Volume2
Issue numberSUPPL. 2
StatePublished - Dec 1 1998

Fingerprint

Antipsychotic Agents
Schizophrenia
olanzapine
Risperidone
Clozapine
Therapeutics
Sensory Receptor Cells
Pharmaceutical Preparations
sertindole

Keywords

  • Clozapine
  • Olanzapine
  • Risperidone
  • Schizophrenia
  • Sertindole
  • Treatment resistance

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

How effective are the second generation antipsychotics? / Buckley, Peter.

In: International Journal of Psychiatry in Clinical Practice, Vol. 2, No. SUPPL. 2, 01.12.1998.

Research output: Contribution to journalReview article

@article{736f24ccb9d24cb5abd1831a91d5a1a0,
title = "How effective are the second generation antipsychotics?",
abstract = "The past five years have witnessed a period of intense drug development for the treatment of schizophrenia. Second generation antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and sertindole are now replacing the conventional antipsychotics in the treatment of schizophrenia at each point along its illness course. While there are few studies comparing these drugs, available evidence and clinical experience suggest that their different neuroreceptor affinity profiles translate into different benefits within specific clinical situations. Their relative efficacy in treatment- refractory schizophrenia and in the management of negative symptoms is of particular importance. While clozapine is currently the treatment of choice in treatment-refractory schizophrenia, there are some data to suggest that risperidone, olanzapine and sertindole are also effective in these patients, although higher doses may be required for the treatment of patients with severe schizophrenia. The benefit of second generation antipsychotics over conventional agents in the treatment of negative symptoms is more established. However, their relative efficacy on primary and secondary negative symptoms appears to differ. Thus, although the advantages of the second generation antipsychotics over conventional agents are acknowledged, there is a clear need for head-to-head comparisons to determine their relative efficacy in treatment-refractory schizophrenia and in the control of negative symptoms.",
keywords = "Clozapine, Olanzapine, Risperidone, Schizophrenia, Sertindole, Treatment resistance",
author = "Peter Buckley",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "SUPPL. 2",

}

TY - JOUR

T1 - How effective are the second generation antipsychotics?

AU - Buckley, Peter

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The past five years have witnessed a period of intense drug development for the treatment of schizophrenia. Second generation antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and sertindole are now replacing the conventional antipsychotics in the treatment of schizophrenia at each point along its illness course. While there are few studies comparing these drugs, available evidence and clinical experience suggest that their different neuroreceptor affinity profiles translate into different benefits within specific clinical situations. Their relative efficacy in treatment- refractory schizophrenia and in the management of negative symptoms is of particular importance. While clozapine is currently the treatment of choice in treatment-refractory schizophrenia, there are some data to suggest that risperidone, olanzapine and sertindole are also effective in these patients, although higher doses may be required for the treatment of patients with severe schizophrenia. The benefit of second generation antipsychotics over conventional agents in the treatment of negative symptoms is more established. However, their relative efficacy on primary and secondary negative symptoms appears to differ. Thus, although the advantages of the second generation antipsychotics over conventional agents are acknowledged, there is a clear need for head-to-head comparisons to determine their relative efficacy in treatment-refractory schizophrenia and in the control of negative symptoms.

AB - The past five years have witnessed a period of intense drug development for the treatment of schizophrenia. Second generation antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and sertindole are now replacing the conventional antipsychotics in the treatment of schizophrenia at each point along its illness course. While there are few studies comparing these drugs, available evidence and clinical experience suggest that their different neuroreceptor affinity profiles translate into different benefits within specific clinical situations. Their relative efficacy in treatment- refractory schizophrenia and in the management of negative symptoms is of particular importance. While clozapine is currently the treatment of choice in treatment-refractory schizophrenia, there are some data to suggest that risperidone, olanzapine and sertindole are also effective in these patients, although higher doses may be required for the treatment of patients with severe schizophrenia. The benefit of second generation antipsychotics over conventional agents in the treatment of negative symptoms is more established. However, their relative efficacy on primary and secondary negative symptoms appears to differ. Thus, although the advantages of the second generation antipsychotics over conventional agents are acknowledged, there is a clear need for head-to-head comparisons to determine their relative efficacy in treatment-refractory schizophrenia and in the control of negative symptoms.

KW - Clozapine

KW - Olanzapine

KW - Risperidone

KW - Schizophrenia

KW - Sertindole

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=0032427618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032427618&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0032427618

VL - 2

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - SUPPL. 2

ER -